- Home
- CVKD vs INKT Comparison
CVKD vs INKT Comparison
Compare CVKD & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- INKT
- Stock Information
- Founded
- CVKD 2022
- INKT 2017
- Country
- CVKD United States
- INKT United States
- Employees
- CVKD N/A
- INKT N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- INKT Medicinal Chemicals and Botanical Products
- Sector
- CVKD Health Care
- INKT Health Care
- Exchange
- CVKD Nasdaq
- INKT Nasdaq
- Market Cap
- CVKD 29.5M
- INKT 28.9M
- IPO Year
- CVKD 2023
- INKT 2021
- Fundamental
- Price
- CVKD $12.32
- INKT $7.25
- Analyst Decision
- CVKD Strong Buy
- INKT Strong Buy
- Analyst Count
- CVKD 1
- INKT 2
- Target Price
- CVKD $32.00
- INKT $37.50
- AVG Volume (30 Days)
- CVKD 20.0K
- INKT 3.0K
- Earning Date
- CVKD 08-06-2025
- INKT 08-12-2025
- Dividend Yield
- CVKD N/A
- INKT N/A
- EPS Growth
- CVKD N/A
- INKT N/A
- EPS
- CVKD N/A
- INKT N/A
- Revenue
- CVKD N/A
- INKT N/A
- Revenue This Year
- CVKD N/A
- INKT N/A
- Revenue Next Year
- CVKD N/A
- INKT N/A
- P/E Ratio
- CVKD N/A
- INKT N/A
- Revenue Growth
- CVKD N/A
- INKT N/A
- 52 Week Low
- CVKD $5.70
- INKT $4.56
- 52 Week High
- CVKD $22.90
- INKT $13.79
- Technical
- Relative Strength Index (RSI)
- CVKD 38.54
- INKT 47.35
- Support Level
- CVKD $13.12
- INKT $7.20
- Resistance Level
- CVKD $15.99
- INKT $7.57
- Average True Range (ATR)
- CVKD 0.76
- INKT 0.17
- MACD
- CVKD -0.08
- INKT 0.03
- Stochastic Oscillator
- CVKD 6.45
- INKT 44.07
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.